Simulations Plus Stock
Price
Target price
-
-
-
-
-
?46.58
WKN: 924294 / Symbol: SLP / Name: Simulations Plus / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Simulations Plus Stock
The community is currently still undecided about Simulations Plus with 1 Buy predictions and 0 Sell predictions.
With a target price of 46 € there is a positive potential of 35.29% for Simulations Plus compared to the current price of 34.0 €.
Pros and Cons of Simulations Plus in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Simulations Plus vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Simulations Plus | - | - | - | - | - | - | - |
| MicroVision Inc | 5.960% | 7.370% | -11.622% | -16.657% | -43.932% | -93.522% | 50.318% |
| Fonar Corp. New | -1.340% | -5.161% | -25.758% | 5.000% | -16.949% | -0.676% | -19.943% |
| Allscripts Healthcare | -6.760% | -6.757% | 6.154% | -36.697% | -25.405% | -47.727% | -19.147% |
Comments
Simulations Plus, Inc. (NASDAQ: SLP) had its price target raised by analysts at Craig Hallum from $50.00 to $51.00. They now have a "buy" rating on the stock.
Show more
Ratings data for SLP provided by MarketBeat
Simulations Plus, Inc. (NASDAQ: SLP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $65.00 price target on the stock.
Show more
Ratings data for SLP provided by MarketBeat
News
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.